Hematopoietic Lineage Transcriptome Stability and Representation in PAXgene™ Collected Peripheral Blood Utilising SPIA Single-Stranded cDNA Probes for Microarray

Laura Kennedy¹*, J. Keith Vass¹*, D. Ross Haggart¹, Steve Moore¹, Michael E. Burczynski², Dan Crowther¹ and Gino Miele¹

¹Translational Medicine Research Collaboration Laboratory, Sir James Black Centre, University of Dundee, Dundee, DD1 5EH, U.K. ²Biomarker Laboratory, Wyeth Research, Collegeville, U.S.A. *Authors equally contributed to this work.

Abstract: Peripheral blood as a surrogate tissue for transcriptome profiling holds great promise for the discovery of diagnostic and prognostic disease biomarkers, particularly when target tissues of disease are not readily available. To maximize the reliability of gene expression data generated from clinical blood samples, both the sample collection and the microarray probe generation methods should be optimized to provide stabilized, reproducible and representative gene expression profiles faithfully representing the transcriptional profiles of the constituent blood cell types present in the circulation. Given the increasing innovation in this field in recent years, we investigated a combination of methodological advances in both RNA stabilisation and microarray probe generation with the goal of achieving robust, reliable and representative transcriptional profiles from whole blood. To assess the whole blood profiles, the transcriptomes of purified blood cell types were measured and compared with the global transcriptomes measured in whole blood. The results demonstrate that a combination of PAXgene™ RNA stabilising technology and single-stranded cDNA probe generation afforded by the NuGEN Ovation RNA amplification system V2™ enables an approach that yields faithful representation of specific hematopoietic cell lineage transcriptomes in whole blood without the necessity for prior sample fractionation, cell enrichment or globin reduction. Storage stability assessments of the PAXgene™ blood samples also advocate a short, fixed room temperature storage time for all PAXgene™ blood samples collected for the purposes of global transcriptional profiling in clinical studies.

Keywords: biomarkers, whole blood, globin reduction, paxgene™, NuGEN™

Introduction

Development of high-quality biomarkers for disease progression, target engagement, pharmacodynamic effects and compound efficacy is central to translational research efforts aimed at establishing personalised medicine. However, identification of such biomarkers is frequently hampered by lack of access to target tissues with direct biological involvement. As such, peripheral blood (PB) has become an increasingly attractive source of surrogate material in place of target tissue as a focus for biomarker discovery and application, representing one of the most widely available and practical sources of biological material collected within the clinic and permitting a largely non-invasive method of repeated analyses within the same patient (Burczynski and Dorner, 2006).

In diseases such as autoimmune disorders and leukaemias, where PB lineages are directly involved in the disease process, disease-associated transcriptional profiles have been well established (Alizadeh et al. 2000; Baechler et al. 2003; Bullinger et al. 2004; Crow and Wohlgemuth, 2003; Golub et al. 1999; Han et al. 2003; Maas et al. 2002; McLean et al. 2004; Moos et al. 2002; Nowicki et al. 2003; Valk et al. 2004; Bennett et al. 2003). In recent years interest has also turned to the potential of PB as a surrogate tissue for the discovery of additional types of biomarkers in other scenarios. Given the highly dynamic cellular nature of the blood and its circulation throughout the body, it is likely that systemic responses to a disease state can be captured within the PB transcriptome. Several examples of successful biomarker discovery in transcriptome data derived from PB to date have been reported from pilot studies in neurological disorders (Borovecki et al. 2005; Hershey et al. 2004; Tang et al. 2005; Moore et al. 2005), oncology settings (Twine et al. 2003; Burczynski et al. 2005), SARS (Yu et al. 2005) and
gastrointestinal disorders (Burczynski et al. 2006). This accumulating body of evidence supports the utility of peripheral blood transcriptional profiling for identification of biomarkers that may function as biomarkers of disease, evidence of pharmacodynamic effect, or even predictors of clinical outcomes and risk of toxicity. Whilst peripheral blood transcriptional profiling appears to hold great promise, there are several limitations to use of this matrix for gene expression studies that should be carefully considered in any study for resulting disease of pharmacodynamic biomarkers to hold any clinical utility (Mohr and Liew, 2007).

Transcriptional profiling from PB can be achieved using a number of methodologies and associated workflows; for example a) whole blood, b) enriched mononuclear fractions (PBMCs) or c) selected/enriched specific hematopoietic lineages. Naturally, each of these approaches possess distinct advantages and disadvantages. Hematopoietic lineage representation in PBMCs or selected/enriched fractions, whilst not requiring introduction of globin reduction strategies prior to microarray experiments, is naturally restricted to the lineages under study and several cell lineages are consequently omitted from further analysis. Global profiling of whole blood RNA, although preferable in order to capture the blood transcriptome in its entirety, has traditionally required globin reduction strategies prior to probe generation for microarray analysis in order to reduce the interference of globin transcripts with array probes. In addition to increasing processing steps, these procedures add the risk of artefactual modulation of the transcriptome and the utility of globin reduction strategies have been questioned in several reports (Liu et al. 2006; Li et al. 2008; Dumeaux et al. 2008).

The consistency of gene expression profiling data of whole blood is highly dependant on the sample stabilisation method used at phlebotomy or during storage (Debey et al. 2006; Rainen et al. 2002). Technologies for whole blood sample collection and storage exist, designed in an attempt to overcome problems associated with clinical collection and PB transcriptome stability. One of these, the PAXgene™ Blood RNA system (PreAnalytiX, Hornbrechtikon, Switzerland) consists of an evacuated PAXgene™ RNA tube for blood collection and a processing kit for isolation of total RNA from whole blood. The PAXgene™ collection tube contains a proprietary reagent that is reported to immediately stabilise intracellular RNA for up to 3 days at room temperature. The potential to minimize the requirement for urgent sample processing by increasing the clinical sample transcriptome stability in this matrix is central to the discovery of robust biomarkers.

Several groups have demonstrated the impact of PAXgene™ blood collection on RNA transcript stabilisation using quantitative PCR (qPCR) analyses. These studies have demonstrated the utility of the PAXgene™ system in restricting both initial and longer term (several days) ex vivo gene expression changes occurring after phlebotomy compared to conventional anticoagulant methods for blood collection (Muller et al. 2002; Pahl and Brune, 2002; Rainen et al. 2002; Thorn et al. 2005). The impact of different PAXgene™ storage protocols on RNA quantity and quality has also been investigated with several reports obtaining high quality RNA samples over a range (2 hrs, 9 hrs, 24 hrs and 5 days) of storage times at room temperature (Chai et al. 2005; Thach et al. 2003; Wang et al. 2004). When generating gene expression data using qPCR of selected transcripts as the biological readout, good comparisons between replicate samples has been shown, although variability between samples increases with longer incubation periods (Wang et al. 2004). Gene expression levels of a limited number of transcripts in PAXgene™-collected whole blood following 5 days room temperature storage have shown no alteration (Chai et al. 2005) compared to 24 hour storage. Conversely, a reduction in RNA integrity after storage in PAXgene™ at room temperature from 1 to 7 days has been reported and, even without apparent reduction in RNA integrity, specific transcript instability has been reported even with storage at + 4 °C rather than room temperature (Kagedal et al. 2005). Considering the potential clinical impact of obtaining high quality and faithful gene expression profiling from peripheral blood, it is crucial to establish a consistent, robust and practical sample collection method for clinical blood samples.

Due to the high level of reticulocytes in peripheral blood there is a predominance of globin mRNA transcripts with the potential to (a) result in under-representation of non-globin transcripts and (b) impact on microarray data quality as a result of extensive non-specific cross-hybridisation to non-globin probes reducing visualisation of non-globin transcripts. Therefore, the quality and
Whole blood transcriptional profiling

The accuracy of gene expression profiles obtained from peripheral blood is highly reliant on the effectiveness of globin reduction carried out prior to microarray probe generation. Technologies available to reduce globin mRNA have been shown to efficiently increase the sensitivity of transcript detection (Field et al. 2007; Li et al. 2008; Liu et al. 2006) but can also reduce the signal intensities achieved for some genes (Field et al. 2007). Importantly, methods of globin reduction have also been shown to introduce changes in the transcriptome profile observed (Feezor et al. 2004; Liu et al. 2006). A potential solution to the problem of globin reduction prior to gene expression profiling of whole blood has been launched by NuGEN Technologies™ (California, U.S.A.) in the form of the Ovation™ RNA amplification system V2. The Ovation system utilises a single primer, isothermal linear amplification (SPIA) method (Kurn et al. 2005) to generate single-strand cDNA microarray probes suitable for use with Affymetrix GeneChips™. Reproducibility studies and comparison to other microarray methods have illustrated a high degree of consistency and greater hybridisation specificity when exploiting ssDNA:DNA hybridisation compared to cRNA:DNA on microarrays (Barker et al. 2005). The NuGEN™ Ovation Whole Blood System does not require globin reduction strategies. Whilst globin transcripts are still converted to ssDNA, the high abundance of these do not present an issue in microarray hybridisations due to the increased specificity of ssDNA probes compared to cRNA probes. This system therefore has the potential to allow whole blood transcriptional profiling with decreased sample processing steps and circumvention of potential artefactual modulation of the transcriptome associated with globin reduction strategies. Ultimately, the utility of any whole blood profiling approach is dependent on its ability to provide a faithful representation of the individual hematopoietic lineage transcriptomes present in blood.

In the present study we therefore sought to identify a workflow which potentially allows (a) efficient and immediate stabilisation of collected peripheral whole blood and (b) microarray probe generation without the requirement for globin reduction. In addition to establishing the robustness and reproducibility of such methods, we also gauged the representation of specific hematopoietic lineage transcriptomes afforded by the evaluated approaches in order to identify an optimal workflow.

**Materials and Methods**

**Sample collection and processing**

Blood samples were collected from an appropriately consented healthy donor using the PAXgene™ collection tube system (PreAnalytIX, Hornbrectikon, Switzerland). Blood was drawn by standard phlebotomy procedures, with 2.5 ml dispensed into each of 6 PAXgene™ tubes and processed according to the manufacturer’s directions (Fig. 1). Briefly, half of the samples collected (n = 3) were maintained at room temperature for 2 hrs and the other half for...

![Figure 1. Experiment workflow utilised for storage and processing of PAXgene™-collected whole blood.](image-url)
24 hrs, both within the manufacturers’ stated period of storage stability of 2–72 hrs. All samples were inverted 10 times and frozen at −20 °C overnight and then moved to −80 °C for storage until RNA isolation (Experiment 1). This same experimental procedure was repeated using a fresh blood draw obtained from the same donor on a separate day (Experiment 2).

Additional blood samples from the same subject were collected into K$_3$-EDTA tubes and processed for full blood counts on a Sysmex XE 2100 fully automated full blood count analyser.

**Total RNA isolation**

Frozen PAXgene™ tubes were thawed at room temperature for 2 hours followed by total RNA isolation according to the manufacturers’ instructions (PreAnalytiX, Hornbrechtikon, Switzerland). Briefly, PAXgene™ blood tubes were centrifuged for 10 minutes at 3000 × g, the supernatant removed and the cell pellet resuspended in 4 ml of RNase-free water. Samples were re-centrifuged for 10 minutes at 3000 × g and the supernatant removed. The cell pellet was resuspended in 350 μl Buffer BR1 and following the addition of 300 μl Buffer BR2 and 40 μl Proteinase K incubated for 10 minutes at 55 °C while shaking at 400 rpm. The resultant lysate was centrifuged through a PAXgene™ Shredder spin column at 16,300 × g for 3 minutes. The supernatant of the flow through was added to 350 μl of 100% ethanol, mixed and applied to a PAXgene™ RNA spin column and centrifuged for 1 minute at 16,300 × g. A DNase I incubation mix was prepared by combining 10 μl of DNase I and 70 μl of Buffer RDD per sample. DNase treatment was performed by pipetting 80 μl of DNase I incubation mix directly on to the PAXgene™ RNA spin column membrane and incubating at room temperature for 15 minutes. To wash the PAXgene™ RNA spin column 350 μl of Buffer BR3 was added and centrifuged for 1 minute at 16,300 × g. 500 μl of Buffer BR4 was added to the PAXgene™ RNA spin column and centrifuged for 1 minute at 16,300 × g. A DNase I incubation mix was prepared by combining 10 μl of DNase I and 70 μl of Buffer RDD per sample. DNase treatment was performed by pipetting 80 μl of DNase I incubation mix directly on to the PAXgene™ RNA spin column membrane and incubating at room temperature for 15 minutes. To wash the PAXgene™ RNA spin column 350 μl of Buffer BR3 was added and centrifuged for 1 minute at 16,300 × g. 500 μl of Buffer BR4 was added to the PAXgene™ RNA spin column and centrifuged for 1 minute at 16,300 × g. The addition of Buffer BR4 was repeated with a 3 minute 16,300 × g centrifugation followed by additional centrifugation for 1 minute at 16,300 × g to dry the column. RNA was eluted into a fresh 1.5 ml microcentrifuge tube using 40 μl of Buffer BR5 followed centrifugation for 1 minute at 16,300 × g. Elution was repeated with 40 μl of fresh Buffer BR5 giving a total elution volume of 80 μl. Eluted RNA was denatured for downstream applications by incubation at 65 °C for 5 minutes. Total RNA concentration was measured by Nanodrop ND-8000 (Nanodrop Technologies, Wilmington, DE, USE), and the integrity of the extracted total RNA was assessed using RNA Nano Chips on an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, U.S.A). Agilent Bioanalyzer 2100 electropherograms were analysed by the Biosizing software 2100 Expert Version B.02.03.SI307 (Agilent Technologies, 2100 Bioanalyzer) to generate RNA integrity numbers (RIN) as an RNA quality control metric.

**Hematopoietic cell lineages**

Hematopoietic cell lineage transcript expression data was obtained from a number of sources (see Table 4). RNA derived in-house (B-cells, T-cells and Dendritic cells) for microarray hybridisation was obtained from frozen cell preparations purchased from Lonza Biosciences (Basel, Switzerland). Transcript expression data for a wide range of other cell lineages were obtained from public datasets deposited in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/), accession numbers GSE1133 and GSE3982 (Jeffrey et al. 2006; Su et al. 2004). Taken together this dataset provided a source of mRNA expression data (derived from Affymetrix GeneChips™) from a wide range of hematopoietic cell lineages prepared by either density gradient, positive or negative paramagnetic bead isolation, and with or without stimulated differentiation in vitro.

**Microarray probe generation**

Preparation of single stranded cDNA (sscDNA) cDNA standards for microarray hybridisation, without the requirement for globin reduction pretreatment, was carried out with 50 ng of total PAXgene™ RNA using NuGEN Technologies (California, U.S.A.) Ovation™ RNA amplification system V2 according to the manufacturers’ instructions. Synthesised sscDNA probe concentration was measured by Nanodrop ND-8000 (Nanodrop Technologies, Wilmington, DE, U.S.A.). The NuGEN Technologies FL-Ovation™ cDNA Biotin
Module V2 was used for sscDNA fragmentation and biotin labelling of 4.4 μg of the amplified sscDNA for subsequent hybridisation to the microarrays (Affymetrix, Santa Clara, CA, U.S.A). The quality of the sscDNA probes was assessed before and after fragmentation with the Agilent 2100 Bioanalyzer using RNA Nano chips (Agilent Technologies, Santa Clara, CA, U.S.A).

RNA (2 μg) prepared in-house from B-cells, T-cells and Dendritic cells was converted to cRNA, further processed according to Affymetrix (Santa Clara, CA, U.S.A) recommendations and quality assessed by Agilent 2100 Bioanalyzer.

Nanodrop ND-8000 and Agilent 2100 Bioanalyzer were also utilised for concentration and quality assessment of sscDNA generated by NuGEN Ovation™ RNA amplification system V2 (Table 1, Fig. 2).

**Affymetrix GeneChips**

For in-house prepared B-cell, T-cell and dendritic cell data, 15 μg of fragmented cRNA was hybridised to Affymetrix HG-U133A GeneChips, according to standard Affymetrix procedures. Data from GSE11133 and GSE3982 also resulted from hybridisation to HG-U133A GeneChips.

sscDNA probes generated from RNA isolated from PAXgene™ collected blood were hybridised to Affymetrix Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA, U.S.A.) as described in the Affymetrix Expression Analysis Technical Manual. Briefly, 4.4 μg of fragmented and labelled sscDNA, together with spiked hybridisation controls (GeneChip Expression 3’ Amplification Reagents—hybridisation controls), was hybridised for 18 hrs at 45 °C in a rotating oven. Following hybridisation GeneChip washing and staining was performed using the GeneChip Hybridisation Wash and Stain kit (Affymetrix, Santa Clara, CA, U.S.A.) on an Affymetrix GeneChip Fluidics Station 450 using the appropriate fluidic script for the U133 Plus 2.0 microarrays with sscDNA (FS450-0004). GeneChips were scanned immediately following staining in an Affymetrix GeneChip Scanner 3000 (Affymetrix, Santa Clara, U.S.A).

**Data analysis**

Report files summarising the quality of target and control detection for each microarray were generated by GeneChip Operating Software Version 1.4 (GCOS) using the MAS5.0 algorithm (Affymetrix, Santa Clara, CA, U.S.A). All parameters (noise factor, background, and scaling factor) were acceptable by Affymetrix recommendations (Table 2).

Assessment of PAXgene™ / NuGEN™ sscDNA whole blood data was performed using a combination of Affymetrix MAS5.0 feature extraction and RMA (Irizarry et al. 2003). Briefly, those probesets determined by MAS5.0 to be present in at least 25% of the PAXgene™ whole blood samples were selected for downstream analyses. Array files were subsequently processed by RMA, filtered on those MAS5.0-selected probesets. Data were Log2-transformed and those probesets with values greater than 6.5 in at least one sample selected for further analysis. Comparison between 2 hrs and 24 hrs PAXgene™ storage was performed by SAM analysis (Tusher et al. 2001) implemented in TM4 MEV (multi-experiment viewer) (Saeed et al. 2003) and using all samples, from both experiments 1 and 2 together, with a False Discovery Rate (FDR) of 0.05.

**Table 1. Yield and quality metrics for isolated total RNA and synthesized single stranded cDNA probes.**

| Experiment | Storage time (hours) | RNA yield (μg/ml) | Bioanalyser RIN | sscDNA yield (μg) |
|------------|----------------------|------------------|-----------------|------------------|
| 1          | 2                    | 5.58 ± (0.19)    | 8.2 ± (0.05)    | 9.7 ± (0.43)     |
| 2          | 24                   | 5.94 ± (0.24)    | 8.8 ± (0.10)    | 9.3 ± (0.27)     |
| 3          | 24                   | 5.85 ± (0.31)    | 8.5 ± (0.07)    | 9.8 ± (0.25)     |

Mean quality metrics for total RNA isolated from 2 hrs (n = 3) and 24 hrs (n = 3) stored PAXgene™ whole blood samples from both experiments 1 and 2 are indicated. Numbers in parenthesis represent s.e.m. Storage time refers to the period the PAXgene™ collected whole blood samples were stored at room temperature prior to storage at −20 °C. Room temperature incubations are a model of the period samples spend in the clinic or in transit before processing by the appropriate laboratory. RNA quality metrics were obtained by Nanodrop ND-8000 spectrophotometry and by Agilent 2100 Bioanalyzer. RIN; RNA Integrity Number.
For assessment of any 3’ or 5’ bias of probeset signal intensity the chromosomal location of probesets were mapped from Affymetrix NetAffx annotation, allowing assessment of bias of signal intensity for those transcripts containing two or more probesets at distinct positions of the corresponding transcript.

To identify probesets most indicative of specific hematopoietic lineages, SAM analysis was performed with an FDR of 0 to select probesets significantly over-represented in one cell type compared to all other cell types within the same dataset. Following identification of probesets significantly over-represented in one particular lineage we applied a second filtering criterion of exclusion of those probesets with linear expression levels of less than 200 to maximise the likelihood of relevance of identified probesets being “diagnostic” of specific hematopoietic lineages.

Results

RNA yield and quality

In order to assess the yield and quality of the RNA obtained following PAXgene™ RNA stabilisation and isolation according to the workflow outlined in Figure 1, quality control analyses were carried out and yields are presented in Table 1. Analysis of total RNA quality by Agilent Bioanalyzer generated showed high RIN (RNA integrity numbers) for all samples (Table 1), revealing good quality RNA above the level traditionally deemed acceptable for microarray probe generation (RIN = 7.0) (Fig. 2, A). No significant differences in yield or quality of RNA obtained from samples collected (a) in different experiments or (b) as a result of PAXgene™ storage time were noted.

Efficacy of sscDNA probe preparation from PAXgene™ whole blood RNA

All RNA samples were used to synthesize sscDNA probes for use in microarray gene expression profiling. Yields of sscDNA within the same experiments are tightly grouped and no significant difference between experiments or as a result of incubation times were observed (Table 1). sscDNA yields were consistently in excess of the 4.4 μg required for further processing for array hybridisation. Quality assessment by Agilent Bioanalyzer shows that the sscDNA fragments generated from whole blood RNA are of broad distribution in length, averaging approximately 1000 nucleotides, suggesting efficient sscDNA synthesis (Fig. 2, B). sscDNAs were fragmented and biotin-labelled in preparation for hybridisation and all resulted in fragments of ~50–200 nt (data not shown), similar to results previously reported using this method (Barker et al. 2005).

Quality of microarray measurements

High quality control metrics for both RNA and sscDNA indicated successful sample preparation and all were subsequently hybridised to Affymetrix
Whole blood transcriptional profiling

Biomarker Insights 2008:3 409

Table 2. Quality metrics following hybridisation of ssDNA probes generated from whole blood RNA to Affymetrix Human Genome U133 Plus 2.0 Arrays.

| Experiment | Storage time (hours) | % Present | Mean% present | Mean actin 3’5’ ratio | Mean GAPDH 3’5’ ratio |
|------------|----------------------|-----------|---------------|----------------------|----------------------|
| 1          | 2                    | 62.5      | 62.1 + (0.64) | 2.06 + (0.04)        | 1.59 + (0.01)        |
| 1          | 24                   | 62.6      | 62.7 + (0.63) | 2.23 + (0.08)        | 1.51 + (0.03)        |
| 2          | 2                    | 62.5      | 62.3 + (0.44) | 2.47 + (0.13)        | 1.67 + (0.04)        |
| 2          | 24                   | 61.8      | 61.5 + (0.63) | 2.52 + (0.20)        | 1.63 + (0.07)        |

Mean quality metrics for microarrays from hybridisation of ssDNA generated from PAXgene™ whole blood RNA stored for 2 hrs (n = 3) and 24 hrs (n = 3). PAXgene™ whole blood samples from both experiments 1 and 2 are indicated. Numbers in parenthesis represent s.e.m. Quality metrics reflect GCOS report data generated following MAS5.0 feature extraction.

Human Genome U133 Plus 2.0 Arrays. All arrays within the study generated percentage present calls of between 60%–63%. Average background was 32.80 ± 0.31 (mean ± standard error), within the typical range of 20–100, the average noise factor was 1.43 ± 0.04 and the average scaling factor for all arrays was 1.56 ± 0.08. Finally, the β-actin 3’–5’ ratio were consistent between all arrays suggesting no significant degradation of samples. Neither experiment or incubation period of PAXgene™ whole blood contributed to any variation in quality control metrics (Table 2).

Hematopoietic transcriptome stability in PAXgene™ Whole Blood samples

Following data normalisation, transformation and filtering, as outlined in materials and methods, Principal Component Analysis of remaining probesets was performed (Fig. 3a). As would be expected, distinct groupings of data according to experimental day were evident. Similarly, the PCA model revealed significant influence of PAXgene™ whole blood incubation period to variance within the dataset, for both experiments. SAM analysis was used with an FDR of 0.05 to identify those probesets differing in expression level in PAXgene™ whole blood samples stored at 24 hrs relative to 2 hrs. Those probesets fulfilling these criteria and which differ in expression level greater than 1.5-fold in 24 hr samples relative to 2 hrs are represented graphically in Figure 3b. This analysis identified a total of 3311 probesets differentially represented in PAXgene™ collected whole blood incubated at room temperature for 24 hrs compared to 2 hrs. The vast majority of these, 3050 (92.1%), represent probesets with lower signal intensities in 24 hr relative to 2 hr samples. Whilst a large amount of these (78.6%) are relatively modest 1.5 to 2-fold changes, a significant number are differentially represented at levels greater than 2-fold, with only 4 of these representing probesets over-represented in 24 hr samples. The complete annotated list of these probesets is available as Supplementary online Table 1.

We first considered the possibility whether those probesets under-represented in 24 hr samples were indicative of canonical degradation of mRNAs. To assess whether these could be due to 5’–3’ degradation of the mRNA transcripts we exploited the fact that several transcripts are represented by 2 or more probesets on the Affymetrix Human Genome U133 Plus 2.0 Arrays. The Affymetrix annotation file allows us to map the chromosomal location of these multiple probesets for the genes showing differential expression between 2 hrs and 24 hrs storage. This then allowed identification of which probeset is responsible for reduced signal intensity in the 24 hrs samples and subsequent assessment of whether this was due to a loss of the 3’ or 5’ probesets. Most genes were excluded from
Figure 3. Analyses of array data derived from hybridisation of ssDNA probes generated from PAXgene™ collected whole blood RNA. (a) Principal Component Analysis of those probesets remaining after filtering for (i) present call by MAS5.0 in at least 25% of samples and (ii) signal intensity greater than 6.5 (Log$_2$) in at least one sample following RMA processing of probesets derived from (i). Squares, experiment 1; triangles, experiment 2; blue, 2 hrs incubation; red, 24 hrs incubation. (b) Graphical representation of the number of probesets determined to be over- or under-represented in 24 hr compared to 2 hr stored samples following SAM analysis with an FDR of 0.05 and fold change ≥1.5. The number of probesets within each fold change range is indicated.
these analyses due to the presence of only one probeset or multiple probesets mapping to overlapping chromosomal regions. In total 117 transcripts were utilised to investigate a potential polarity effect (i.e. 3' or 5' degradation). Interestingly, of these 117 genes a clear degradation effect was observed with 94 genes displaying preferential loss of a 3' probeset and only 23 genes showing loss of a 5' probeset suggesting highly significant ($P < 1 \times 10^{-7}$, repeat random sampling) 3' degradation.

Faithfulness of hematopoietic cell lineage transcriptome representation in PAXgene™ whole blood expression profiles

It is essential that any workflow utilising whole blood provides a faithful representation of individual cell lineage transcriptomes. We wished to have an objective measurement of the probesets we had identified as “present” in our PAXgene™ analyses compared to probesets independently identified from samples where specific haematopoietic cell lineages had been isolated as being indicative of the identity of that particular lineage. We pursued this approach with the additional intention of investigating whether the marked under-representation of a large number of probesets following 24 hr PAXgene™ whole blood storage resulted from preferential reduction in signal intensity of probes accounted for by a particular hematopoietic lineage. ‘Signature probe-sets’ indicative for a number of individual haematopoietic cell lineages were estimated from both in-house and public data sets (Jeffrey et al. 2006; Su et al. 2004). These datasets were generated utilising a wide range of enrichment techniques; positive and/or negative selection and with or without in vitro stimulation and culture from either cord blood or peripheral blood (Table 4). Signature probesets were identified following SAM analysis with an FDR of 0, as indicated in materials and methods, from those found to be significantly over-represented in the cell-type of choice, compare to all other cell-types in that dataset. This data is summarised in Table 4 and the resultant annotated list of lineage-enriched probesets are available as Supplementary online Table 2.

To safeguard against any differences in hematopoietic cell lineages observed between our PAXgene dataset and others being due to abnormal levels of a particular cell lineage from the individual donor used in this study full haematopoietic analysis on blood samples from this individual was carried out and shown to be within healthy boundaries (Table 3).

Probesets determined to be hematopoietic cell lineage enriched remain well represented in the PAXgene™/sscDNA 2 hr/24 hr combined dataset (Table 4, Fig. 4), with several reaching 100% representation. Macrophages and dendritic cell transcript “signatures” appear most-under-represented in the PAXgene™/sscDNA whole blood expression data (71% and 75% respectively). Notably, those probesets determined to be sensitive to PAXgene™ whole blood incubation period do not appear to be contributed to by any particular individual lineage under study. Whilst the high degree of representation of individual hematopoietic lineage transcriptome in PAXgene™/sscDNA data was encouraging it was important to establish that this was not due solely to high abundance transcripts being interrogated. We therefore investigated the relationship between abundance of transcripts identified as being indicative of a particular lineage compared to transcript abundance observed in the PAXgene™/sscDNA data (Fig. 4). The small number of lineage enriched probesets, not represented in the PAXgene™/sscDNA dataset, appear over a range of abundances but are mostly lowly expressed in both the original and PAXgene™ datasets. Importantly, several low abundant genes within the isolated cell data sets are robustly detected in the PAXgene™ dataset (Fig. 4). Interestingly, there is a general concordance between the

Table 3. Donor hematological full blood counts.

| Cell type               | Donor A          |
|------------------------|------------------|
| RBC ($\times 10^{12}$/L) | 5.3 (4.5–6.0)   |
| WBC ($\times 10^{9}$/L)  | 6.3 (4.0–11.0)   |
| Neutrophils ($\times 10^{9}$/L) | 3.4 (2.0–7.5)   |
| Lymphocytes ($\times 10^{9}$/L) | 2.2 (1.5–4.0)   |
| Monocytes ($\times 10^{9}$/L) | 0.4 (0.2–0.8)   |
| Eosinophils ($\times 10^{9}$/L) | 0.25 (0–0.4)    |
| Basophils ($\times 10^{9}$/L) | 0 (0–0.1)       |
| Platelets ($\times 10^{9}$/L) | 198 (150–400)   |

Full haematological analysis of whole blood samples illustrate that all hematopoietic cell lineages are present in concentrations within the normal range in donor A. RBC = Red blood cells, WBC = White blood cells. Parenthesis = ref. range for males.
levels of expression in the original cell-line specific
data and in our PAXgene™ whole blood data set.
There is only low representation (0%–2%) of
any of these lineage specific probesets in those
determined to be unstable as a result of storage
times, therefore no loss of a particular cell lineage
accounts for these changes.

**Discussion**
The ability to robustly detect and measure bio-
logical variation associated with disease or
pharmacologic intervention in whole blood clinical
samples is key to the future discovery of surrogate
disease biomarkers leading to translational research
and personalised medicine. To this end we have
assessed a workflow which allows microarray
gene expression analysis of whole blood using
PAXgene™ RNA stabilisation and subsequent
sscDNA microarray probe generation without the
requirement for globin reduction practices.
Despite claims that PAXgene™ technology
efficiently stabilises whole blood samples for up

---

**Table 4. Source details of hematopoietic cell lineages.**

| Cell type               | Dataset     | Purity | Markers          | Enrichment                                                                 | Positive selection antibody | Origin          |
|-------------------------|-------------|--------|------------------|----------------------------------------------------------------------------|------------------------------|-----------------|
| CD19⁺ B-Cells           | In-house    | >85%   | CD19             | Negative selection                                                        | n/a                          | Cord blood      |
| CD4⁺ T-Cells            | In-house    | >90%   | CD4              | Negative selection                                                        | n/a                          | Peripheral blood|
| Dendritic Cells         | In-house    | >85%   | CD14, CD56       | Leukopheresis and density gradient. *In vitro* differentiation.            | n/a                          | Peripheral blood|
| Eosinophils             | GSE3982     | 97%    | CD16             | Percoll gradient                                                          | n/a                          | Peripheral blood|
| Macrophages             | GSE3982     | Unknown| Unknown          | Ficoll gradient, positive selection, GM-CSF                                | Anti-CD14                    | Peripheral blood|
| Neutrophils             | GSE3982     | >97%   | CD16, CD62L      | Ficoll gradient, negative selection                                        | n/a                          | Peripheral blood|
| B-Cells                 | GSE3982     | >96%   | CD19             | Ficoll gradient, positive selection                                        | Anti-CD19                    | Peripheral blood|
| Basophils               | GSE3982     | >96%   | CCR3             | Ficoll gradient, negative selection followed by positive selection        | Anti-CCR3                    | Peripheral blood|
| NK Cells                | GSE3982     | >96%   | CD16, CD56       | Ficoll gradient, positive selection                                        | Anti-CD16/CD56               | Peripheral blood|
| Immature Dendritic Cells| GSE3982     | Unknown| Unknown          | Ficoll gradient, positive selection, IL14/GM-CSF differentiation           | Anti-CD14                    | Peripheral blood|
| CD14⁺ Monocytes         | GSE1133     | Unknown| CD14             | Density gradient and positive selection                                    | Anti-CD14                    | Peripheral blood|
| CD19⁺ B-Cells           | GSE1133     | Unknown| CD19             | Negative selection                                                        | n/a                          | Peripheral blood|
| CD4⁺/CD8⁺ T-Cells       | GSE1133     | Unknown| CD4/ CD8         | Unknown                                                                     | n/a                          | Peripheral blood|
| CD56⁺ NK Cells          | GSE1133     | >90%   | CD16, CD56       | Unknown                                                                     | n/a                          | Peripheral blood|

Preparation details for datasets utilised for generation of probesets indicative of specific hematopoietic cell lineages are shown for both in-house generated data and GSE3982 and GSE1133. Prepared cells are from a variety of sources and derived by a number of methods, including positive and negative selection (or both) and with or without *in vitro* differentiation procedures.
Figure 4. Scatterplots indicating the representation of lineage-enriched probesets in PAXgene™/sscDNA-derived data. Log₂-transformed expression data for those probesets indicative of specific lineages compared to expression data derived from PAXgene™/sscDNA hybridisations are indicated. Sources of each dataset are noted. Probesets passing the filters outlined in methods and materials but which were determined not to be expressed in the PAXgene™/sscDNA datasets are indicated as filled red circles. DCs, dendritic cells; NK, Natural killer cells.
to 3 days at room temperature, reports of reduced RNA quality with longer PAXgene™ storage and importantly, instability of a small number of studied transcripts despite retention of RNA integrity (Kagedal et al. 2005), within these recommended storage limits, warranted further investigation of transcriptome stability in PAXgene™ collected whole blood. To assess the stability of the entire whole blood transcriptome under storage conditions reflecting likely sample collection schema in clinical environments and within the recommended limits of the PAXgene™ technology we used Affymetrix GeneChip array technology and PAXgene™ collected whole blood stored at room temperature for either 2 or 24 hrs.

Our data demonstrate that PAXgene™ stabilised peripheral blood samples stored at room temperature for either 2 hrs or 24 hrs results in high quality RNA and generate ample ssDNA microarray probes for gene expression analysis, with subsequent arrays being of high quality with significantly high present calls (60%–62%), despite the omission of any globin interference reduction strategies. As would be expected, further analysis of array datasets revealed significant contribution of (a) experimental day and (b) incubation period to overall variance within the data. However, despite the preservation of RNA quality, storage for 24 hrs at room temperature resulted in significant transcriptome alterations compared to storage for 2 hrs.

### Table 5. Representation of probesets indicative of specific hematopoietic cell lineages in the PAXgene™ whole blood / ssDNA dataset.

| Cell type                  | Dataset   | Number of probesets indicative of cell lineage | Number of cell-lineage “signature” probesets present in PAXgene™ / ssDNA dataset | Representation of cell-lineage “signature” probesets present in PAXgene™ / ssDNA dataset (%) | Cell lineage “signature” probesets also identified to be storage time-sensitive (%) |
|---------------------------|-----------|-----------------------------------------------|---------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| CD19⁺ B-Cells             | In-house  | 119                                           | 116                                                                             | 97                                                                                           | 2.0                                                                                 |
| CD4⁺ T-Cells              | In-house  | 34                                            | 34                                                                             | 100                                                                                          | 3.0                                                                                 |
| Dendritic Cells           | In-house  | 52                                            | 39                                                                             | 75                                                                                           | 2.0                                                                                 |
| Eosinophils               | GSE3982   | 78                                            | 73                                                                             | 94                                                                                           | 8.2                                                                                 |
| Macrophages               | GSE3982   | 76                                            | 54                                                                             | 71                                                                                           | 3.7                                                                                 |
| Neutrophils               | GSE3982   | 365                                           | 361                                                                           | 99                                                                                           | 4.1                                                                                 |
| B-Cells                   | GSE3982   | 62                                            | 62                                                                             | 100                                                                                          | 4.8                                                                                 |
| Basophils                 | GSE3982   | 102                                           | 90                                                                             | 88                                                                                           | 8.9                                                                                 |
| NK Cells                  | GSE3982   | 41                                            | 41                                                                             | 100                                                                                          | 0                                                                                    |
| Immature Dendritic Cells  | GSE3982   | 56                                            | 46                                                                             | 82                                                                                           | 0                                                                                    |
| CD14⁺ Monocytes           | GSE1133   | 35                                            | 35                                                                             | 100                                                                                          | 2.9                                                                                 |
| CD19⁺ B-Cells             | GSE1133   | 39                                            | 38                                                                             | 97                                                                                           | 5.3                                                                                 |
| CD4⁺/CD8⁺ T-Cells         | GSE1133   | 224                                           | 209                                                                           | 94                                                                                           | 3.4                                                                                 |
| CD56⁺ NK Cells            | GSE1133   | 106                                           | 99                                                                             | 93                                                                                           | 4.0                                                                                 |

The number of probesets determined, as outlined in the materials and methods section, to be most indicative of specific hematopoietic cell lineages from in-house generated array data and from GSE3982 (Jeffrey et al. 2006) and GSE1133 (Su et al. 2004) are indicated. The number or proportion of these present in processed and filtered data derived from hybridisation of ssDNA probes derived from RNA isolated from PAXgene™ collected whole blood are indicated. The number of those probesets for each lineage which were also identified to be incubation period sensitive is also presented. NK cells; Natural Killer Cells.
with the majority (92.1%) representing probesets under-represented in 24 hr samples at levels greater than 1.5-fold. We interpret this to indicate that intracellular RNA stabilisation is not 100% complete following 2 hrs storage at room temperature. Those transcripts for which we were able to further investigate polarity of any degradation effect substantiated this notion, with significantly lower signal intensity being attributed to the 3' end of transcripts. Whilst this in agreement with incomplete RNA stabilisation it also indicates that this does not necessarily result in canonical RNA degradation, with this data indicating loss of poly(A) sequences, the effects of which would of course be expected to manifest most profoundly in procedures utilising poly(A) tails for reverse transcription. The clinical implication of these findings are significant as variation in sample storage or transportation time will lead to ex vivo transcriptome alterations which may mask any clinically relevant biological variation present within those transcripts affected by storage artefacts. However, it is important to note that Affymetrix expression array GeneChips are focussed to the 3' end of transcripts and this should be considered when evaluating our data in context with competitor microarray platforms.

Whilst size, nucleotide composition, secondary structure properties and abundance of transcripts could all conceivably account in part for the storage time dependent transcriptome alterations noted here we also considered it possible, albeit unlikely after more than 2 hours, that this could indicate differential lysis of a particular hematopoietic lineage within the PAXgene™ lysis matrix, thereby fostering RNA degradation within those cells. Notably, signal intensities of the vast majority (74%) of those transcripts identified as being PAXgene™ storage period sensitive at 24 hrs are within the upper 50% of signal intensity distribution for those probesets obtained at 2 hrs (data not shown), indicating that increased periods of whole blood storage in the PAXgene™ system predominantly affects transcripts of highest abundance.

Comparison of our PAXgene™ sample data set with expression data of transcripts determined to be indicative of specific lineage populations, we demonstrated that the 24 hr under-represented transcripts appeared to be cell-lineage independent. Similarly, pathway mapping analysis did not reveal any obvious networks that could be attributed to cell-specific biological functions (data not shown). The underlying factors influencing transcript specific degradation and significant storage time dependent under-representation within the PAXgene™ samples are therefore undetermined at this time.

Our data are concordant with several reports that RNA integrity remains intact following extended room temperature storage times following PAXgene™ blood sample collection (Chai et al. 2005; Thach et al. 2003; Wang et al. 2004). However, we have shown degradation and significant under-representation of a large number of transcripts following just 24 hrs room temperature storage, supporting previous reports (Kagedal et al. 2005) of sample instability, but contrary to others showing no change in transcript levels up to 5 days of room temperature storage (Chai et al. 2005). It is likely that this latter discrepancy is due to the use of qPCR methods to analyse only a small number of specific transcripts (Chai et al. 2005; Thach et al. 2003; Wang et al. 2004), rather than global profiling approaches. Reports have also compared longer storage times (24 hrs and 5 days) demonstrating no alterations in transcript representation (Chai et al. 2005). However, with the omission of shorter time points interpretation of whether the abundance of these transcripts has already altered from their original basal levels at time of collection is not possible.

We report the generation of high quality global gene expression data from PAXgene™ peripheral blood samples, which we believe will be vital for future biomarker discovery and interrogation within clinical samples. However, considering transcriptome alterations observed within the storage time range recommended by the manufacturers it will be imperative to instigate a fixed storage time for all clinical samples intended for direct comparison within a given study.

A further aim of this study was to assess the suitability of a single-primer isothermal linear amplification (SPIA) method for application with Affymetrix GeneChip microarrays for whole blood transcriptome analysis potentially mitigating the need for globin reduction. Globin reduction practices in whole blood RNA sample processing have previously been shown to alter global gene expression profiles obtained (Feezor et al. 2004; Liu et al. 2006) and significantly increase sample handling. Using this SPIA technology we synthesised high quality sscDNA in ample quantity from PAXgene™ samples to carry out hybridisation to microarrays. sscDNA probes for microarrays have previously been shown to provide high specificity
of hybridisation and consequently provide increased percentage present calls, as a result of reduced cross-hybridisation to mismatch control probes, and with this workflow we achieved a minimum of 60 percent present calls on Affymetrix Genechips. Therefore, we have demonstrated that NuGEN Technologies Whole Blood Ovation™ RNA amplification for probe generation permits analysis of gene expression profiles from whole blood with minimal handling steps without the requirement for potentially transcriptome-modifying globin reduction processing schemes and expression profiling of transcript abundances, thereby supporting the notion that efficient whole blood expression profiling studies can be achieved without requirement for lineage or cell population enrichment strategies and without loss of data contributed by specific lineages. Whilst the high levels of representation of transcripts indicative of specific cell lineages in the PAXgene™ / sscDNA dataset was remarkable, as expected several of these did not reach 100% and we consider this a likely reflection of the methods employed for individual lineage enrichment. Notably, those lineages with lowest representation (approximately 70%) result from enrichment schemes which include subsequent in vitro stimulation and culture and with transcriptome profiles likely least reflective of those lineages in vivo.

We conclude that robust global gene expression profiling from whole blood without the requirement for globin reduction processing schemes and with maximal representation of individual hematopoietic lineages can be achieved by combination of PAXgene™ RNA stabilisation procedures, albeit with careful consideration to fixed incubation periods for all samples within a clinical collection, together with NuGEN Technologies Whole Blood Ovation™ RNA amplification system for microarray probe generation.

Disclosure
The authors report no conflicts of interest.

References
Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.J., Yang, L., Marti, G.E., Moore, T., Hudson, J.JR., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenberger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. and Staub, L.M. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403:503–11.

Bacchler, E.C., Batliwalla, F.M., Karypis, G., Gaffney, P.M., Ommitt, W.A., Espe, K.J., Shark, K.B., Grande, W.J., Hughes, K.M., Kapur, V., Gregersen, P.K. and Behrens, T.W. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U.S.A., 100:2610–5.

Barker, C.S., Griffin, C., Dolganov, G.M., Hanspers, K., Yang, J.Y. and Erle, D.J. 2005. Increased DNA microarray hybridization specificity using ssDNA targets. BMC Genomics, 6:57.

Bennett, L., Palucka, A.K., Arce, E., Cantrell, V., Borvak, J., Banchereau, J. and Pascual, V. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med., 197:711–23.

Borovecki, F., Lovecic, I., Zhou, J., Jeong, H., Then, F., Rosas, H.D., Hersch, S.M., Hogarth, P., Bouzou, B., Jensen, R.V. and Kraine, D. 2005. Genome-wide expression profiling of human blood reveals biomarkers for Huntington’s disease. Proc. Natl. Acad. Sci. U.S.A., 102:11023–8.

Bullinger, L., Dohner, K., Baer, E., Frohling, S., Schleng, R.F., Tibshirani, R., Dohner, H. and Pollack, J.R. 2004. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med., 350:1605–16.

Burczynski, M.E. and Dorner, A.J. 2006. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics, 7:187–202.

Burczynski, M.E., Peterson, R.L., Twine, N.C., Zuberek, K.A., Brodeur, B.J., Casciotti, L., Maganti, V., Reddy, P.S., Strahs, A., Immerrmann, F., Spinelli, W., Schwertschlag, U., Slager, A.M., Croteau, M.M. and Dorner, A.J. 2006. Molecular classification of Crohn’s disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J. Mol. Diagn., 8:51–61.

Burczynski, M.E., Twine, N.C., Dukart, G., Marshall, B., Hidalgo, M., Stadler, W.M., Logan, T., Dutcher, J., Hudes, G., Trepichio, W.L., Strahs, A., Immerrmann, F., Slonim, D.K. and Dorner, A.J. 2005. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin. Cancer Res., 11:1811–9.

Chai, V., Vassilakos, A., Lee, Y., Wright, I.A. and Young, A.H. 2005. Optimization of the PAXgene blood RNA extraction system for gene expression analysis of clinical samples. J. Clin. Lab. Anal., 19:182–8.

Crow, M.K. and Wohlgemuth, J. 2003. Microarray analysis of gene expression in lupus. Arthritis Res. Ther., 5:279–87.

Debey, S., Zander, T., Brors, B., Popov, A., Eils, R. and Schultz, J.L. 2006. A highly standardized, robust, and cost-effective method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials. Genomics, 87:653–64.

Dumeaux, V., Lund, E. and Borresen-Dale, A. 2008. Comparison of globin RNA processing methods for genome-wide transcriptome analysis from whole blood. Biomarkers in Medicine, 2:11–21.

Feczor, R.J., Baker, H.V., Mindrinos, M., Hayden, D., Tannahill, C.L., Brownstein, B.H., Fay, A., Macmillan, S., Laramie, J., Xiao, W., Moldawer, L.L., Cobb, J.P., Laudanski, K., Miller-Graziano, C.L., Maier, R.V., Schoenfeld, D., Davis, R.W. and Tompkins, R.G. 2004. Whole blood and leukocyte RNA isolation for gene expression analyses. Physiol. Genomics, 19:247–54.

Field, L.A., Jordan, R.M., Hadix, J.A., Dunn, M.A., Shrived, C.D., Ellsworth, R.E. and Ellsworth, D.L. 2007. Functional identity of genes detectable in expression profiling assays following globin mRNA reduction of peripheral blood samples. Clin. Biochem., 40:499–502.
Golub, T.R., Slonim, D.K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J.P., Coller, H., Loh, M.L., Downing, J.R., Caligiuri, M.A., Bloomfield, C.D. and Lander, E.S. 1999. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science*, 286:531–7.

Han, G.M., Chen, S.L., Shen, N., Ye, S., Bao, C.D. and Gu, Y.Y. 2003. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. *Genes Immun.*, 4:177–86.

Hershey, A.D., Tang, Y., Powers, S.W., Kabbouche, M.A., Gilbert, D.L., Han, G.M., Chen, S.L., Shen, N., Ye, S., Bao, C.D. and Gu, Y.Y. 2003. Biomarker Insights 2008:3

Kagedal, B., Lindqvist, M., Farneback, M., Lenner, L. and Peterson, C. 2006. Effects of globin mRNA stability in whole blood. *Clin. Chem. Lab. Med.*, 43:1190–7.

Kurn, N., Chen, P., Heath, J.D., Kopf-Sill, A., Stephens, K.M. and Wang, S. 2005. Novel isothermal, linear nucleic acid amplification systems for highly multiplexed applications. *Clin. Chem.*, 51:1973–81.

Li, L., Ying, L., Naens, M., Xiao, W., Sigdel, T., Hsieh, S., Martin, J., Chen, R., Liu, K., Mindrinos, M., Davis, R. and Sarwal, M. 2008. Interference of globin genes with biomarker discovery for allograft rejection lesions from whole blood. *Physiol. Genomics*, 32:9–7.

Liu, J., Walter, E., Stenger, D. and Thach, D. 2006. Effects of globin mRNA reduction methods on gene expression profiles from whole blood. *J. Mol. Diag.*, 8:551–8.

Maas, K., Chan, S., Parker, J., Slater, A., Moore, J., Olsen, N. and Aune, T.M. 2002. Cutting edge: molecular portrait of human autoimmune disease. *J. Immunol.*, 169:5–9.

Mocean, L.A., Gathmann, I., Capdeville, R., Polymenopoulous, M.H. and Dressman, M. 2004. Pharmacogenomic analysis of cyto genetic response in chronic myeloid leukemia patients treated with imatinib. *Clin. Cancer Res.*, 10:155–65.

Mohl, S. and Liew, C.C. 2007. The peripheral-blood transcriptome: new insights into disease and risk assessment. *Trends Mol. Med.*, 13:422–32.

Moore, D.F., Li, H., Jeffries, N., Wright, V., Cooper, R.A., Jr., Elkhailoun, A., Gelderman, M.P., Zudaire, E., Elevins, G., YU, H., Goldin, E. and Baird, A.E. 2005. Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. *Circulation*, 111:212–21.

Moos, P.J., Raetz, E.A., Carlson, M.A., Szabo, A., Smith, F.E., Willman, C., Wei, Q., Hunger, S.P. and Carroll, W.L. 2002. Identification of gene expression profiles that segregate patients with childhood leukemia. *Clin. Cancer Res.*, 8:3118–30.

Muller, M.C., Merx, K., Weiss, A., Kreil, S., Lahaye, T., Hahlmann, R. and Hochhaus, A. 2002. Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. *Leukemia*, 16:2395–9.

Nowicki, M.O., Pawlowski, P., Fischer, T., Hess, G., Pawlowski, T. and Skorski, T. 2003. Chronic myelogenous leukemia molecular signature. *Oncogene*, 22:3952–63.

Pahl, A. and Brune, K. 2002. Stabilization of gene expression profiles in blood after phlebotomy. *Clin. Chem.*, 48:2251–3.

Rainen, L., Oelmuller, U., Jurgensen, S., Wyrich, R., Ballas, C., Schram, J., Herdman, C., Bankaitis-Davis, D., Nicholls, N., Trollering, D. and Tryon, V. 2002. Stabilization of mRNA expression in whole blood samples. *Clin. Chem.*, 48:1883–90.

Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagajaran, M., Sturn, A., Snuffin, M., Rezantsev, A., Popov, D., Ryltsov, A., Kostukovich, E., Borisovsky, I., Liu, Z., Vinsavich, A., Trush, V. and Quackenbush, J. 2003. TM4: a free, open-source system for microarray data management and analysis. *Biotechniques*, 34:374–8.

Sa, A.I., Wiltshire, T., Batalov, S., Lapp, H., Ching, K.A., Block, D., Zhang, J., Soden, R., Hayakawa, M., Kreiman, G., Cooke, M.P., Walker, J. R. and Hogensesh, J.B. 2004. A gene atlas of the mouse and human protein-encoding transcriptomes. *Proc. Natl. Acad. Sci. U.S.A.*, 101:6062–7.

Tang, Y., Gilbert, D.L., Glauser, T.A., Hershey, A.D. and Sharp, F.R. 2005. Blood gene expression profiling of neurologic diseases: a pilot microarray study. *Arch. Neurol.*, 62:210–5.

Thach, D.C., Lin, B., Walter, E., Kruzeloek, R., Rowley, R.K., Tibbetts, C. and Stenger, D.A. 2003. Assessment of two methods for handling blood in collection tubes with RNA stabilizing agent for surveillance of gene expression profiles with high density microarrays. *J. Immunol. Methods*, 283:269–79.

Thorn, I., Olsson-Stromberg, U., Ohlsen, C., Jonsson, A.M., Klangby, U., Simonsson, B. and Barbary, G. 2005. The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia. *Haematologica*, 90:1471–6.

Tusher, V.G., Tibshirani, R. and Chu, G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. *Proc. Natl. Acad. Sci. U.S.A.*, 98:5116–21.

Twine, N.C., Stover, J.A., Marshall, B., Dukart, G., Hidalgo, M., Stadler, W., Logan, T., Dutcher, J., Hudes, G., Dorner, A.J., Slonim, D.K., Trecipchio, W.L. and Burczynski, M.E. 2003. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. *Cancer Res.*, 63:6069–75.

Valck, P.J., Verhaak, R.G., Beijen, M.A., Erpelinck, C.A., Barjesteh Van Waalwijk VAN Doorn-Khosrovani, S., Boer, J.M., Beverloo, H.B., Moorhouse, M.J., Van Der Spek, P.J., Lowenberg, B. and Delwel, R. 2004. Prognostically useful gene-expression profiles in acute myeloid leukemia. *N. Engl. J. Med.*, 350:1617–28.

Wang, J., Robinson, J.F., Khan, H.M., Carter, D.E., Mckinney, J., Miskie, B.A., Hegele, R.A. and 2004. Optimizing RNA extraction yield from whole blood for microarray gene expression analysis. *Clin. Biochem.*, 37:741–4.

Yu, S.Y., Hu, Y.W., Liu, X.Y., Xiong, W., Zhou, Z.T. and Yuan, Z.H. 2005. Expression profiles in peripheral blood mononuclear cells of SARS patients. *World J. Gastroenterol.*, 11:5037–43.